Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Insider Selling in Eli Lilly (LLY) Shares Continues

07/16/2021 | 10:19pm EDT


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
09:13aHealth Care Stocks Mixed Premarket Friday
MT
06:02aABCELLERA BIOLOGICS : Lilly Announce Expanded FDA Emergency Use Authorization fo..
MT
09/16ABCELLERA BIOLOGICS : Jumps 20% After Hours as FDA Expands Emergency Use Authori..
MT
09/16Eli Lilly Gets Expanded FDA EUA for Covid-19 Treatment for Some High-Risk Ind..
DJ
09/16ABCELLERA BIOLOGICS : Lilly Announce Expanded FDA Emergency Use Authorization fo..
MT
09/16The U.S. Food and Drug Expends the Emergency Use Authorization for Lilly's Ba..
CI
09/16Lycia Therapeutics, Inc. announced that it has received $70.055062 million in..
CI
09/15ELI LILLY AND : Secures $300 Million Etesevimab Order From US
MT
09/15REGENERON PHARMACEUTICALS : U.S. buys additional doses of Eli Lilly, Regeneron C..
RE
09/15U.S. buys additional doses of Eli Lilly's COVID-19 therapy
RE
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 191 M - -
Net income 2021 6 346 M - -
Net Debt 2021 11 480 M - -
P/E ratio 2021 33,2x
Yield 2021 1,42%
Capitalization 209 B 209 B -
EV / Sales 2021 8,13x
EV / Sales 2022 7,86x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 231,04 $
Average target price 264,58 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY36.84%209 456
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887
ABBVIE INC.0.87%190 996